The first patient has been enrolled in a phase 2 clinical study evaluating YP-P10 for the treatment of dry eye disease, according to a press release from Yuyu Pharma.
The ICECAP study will include 240 patients at seven U.S. sites and assess the safety, tolerability and efficacy of YP-P10, a novel synthetic peptide with anti-inflammatory and wound healing properties. Earlier this year, the FDA cleared an investigational new drug application for the ophthalmic solution.
According to preclinical data, YP-P10 lowered proinflammatory cytokines and chemokines production in human peripheral blood